NCT05372003View on ClinicalTrials.gov

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

February 23, 2024

Study Completion Date

February 23, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

dupilumab injections will be prescribed and managed by dermatology as standard of care

OTHER

Photo therapy

light therapy will be prescribed and managed by dermatology as standard of care

Trial Locations (1)

85259

Mayo Clinic Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05372003 - IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter